Loading stock analysis…
Evidence Synthesis
Last synthesized: 21 Oct 2026, 03:25
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
INDOAMIN's 34.39% gross margin accelerated to, up from 12.41%.
The company's .41% marginal operating leverage also accelerated. INDOAMIN's revenue growth year-over-year accelerated to 30.3%, up from 6.1%. The daily trading volume increased to 328,179 shares, up from 273,074 shares.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 34.39 % | 12.41 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 12.41 % | 6.52 | ▲ |
| REVENUE_GROWTH_YOY | 30.3 % | 6.1 | ▲ |
| PRICE_CHANGE_PERCENT | -6.367 % | — | - |
| DAILY_VOLUME | 3,28,179 shares | 2,73,074 | ▲ |
| CLOSE_PRICE | 134.7 INR | 143.86 | ▼ |
Cite this
Source: Samhati evidence synthesis for INDOAMIN (2026-10-21). Observation: INDOAMIN's 34.39% gross margin accelerated to, up from 12.41%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/indoamin
Filing step-changes